louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03587324: Perioperative Aspirin Response in Patients Undergoing Vascular Surgery
Official title: Perioperative Risk Factors for the Development of Aspirin Low Response in Patients Undergoing Vascular Surgery.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vascular Surgery Patient With PAD / Carotid Stenosis
Lead sponsor: St. Josef Hospital Bochum
Sponsor class: OTHER
First posted: 2018-07-16
Enrollment: 176
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Reduced antiplatelet activity (low response (LR)/high on-treatment platelet reactivity (HPR)) of aspirin (ALR) or clopidogrel (CLR) is associated with an increased risk of thromboembolic events. The prevalence figures for low-responders reported in the literature vary widely and there have been few investigations in vascular surgery patients to date. The aim of this prospective monocentric study was to increase the evidence base on vascular surgery patients and to detect any changes in the response following vascular surgery procedures.

Detailed description: The activity of aspirin (acetylsalicylic acid, ASA) and clopidogrel is measured by whole blood impedance aggregometry using a multiple electrode aggregometer (Multiplate). The agonists used are arachidonic acid for aspirin and adenosine diphosphate (ADP) for clopidogrel. Vascular patients requiring treatment for peripheral artery disease (PAD) and/or carotid stenosis are included in the study. To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented. In addition, a follow-up aggregometry is performed after completion of the vascular procedure.

Eligibility criteria: Inclusion Criteria:

• Vascular patients requiring treatment for peripheral artery disease (PAD) and/or carotid stenosis are included in the study.

Exclusion Criteria:

* non-adherence to the antiplatelet medication
* abnormal platelet count in patients,
* current gastrointestinal disorders,
* current infections,
* serious concomitant medical conditions (such as recent gastrointestinal bleeding, cancer, severe cardiac or liver disorders)
* known bleeding or coagulation disorders,

Primary outcomes:
measure: Number of Participants Who Were Responders or Low-Responders of Antiplatelet Therapy as a Result of Whole Blood Aggregometry Testing
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bochum
country: Germany
facility: Department of vascular surgery, St. Josef Hospital, Ruhr University of Bochum
state: NRW
Study officials:
References:
Clinical trial NCT04865224: Non-Invasive Estimation of Hemoglobin Levels in Blood Using Combined Deep Learning Methods
Official title: Non-Invasive Estimation of Hemoglobin Levels in Blood Using Combined Deep Learning Methods
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemoglobin Level Measurement
Hemoglobin Level Estimation
Keywords: non-invasive
deep learning
hemoglobin level estimation
Lead sponsor: Karabuk University
Sponsor class: OTHER
First posted: 2021-04-29
Enrollment: 353
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People whose hemoglobin level has been measured in the clinic or laboratory.

Brief summary: Hemoglobin is an important protein that gives the blood its red color and helps transport oxygen to organs. There are quite a lot of people in the world who need to have their hemoglobin levels checked regularly, especially anemia patients. It is important to keep the hemoglobin levels in the blood of these individuals under control. For this, it is necessary to measure in frequent periods. A large group, from adults to children, needs to take these measurements. Most of these are invasive measurements made with blood that require devices and trained people. These painful methods are quite uncomfortable.

In this study, non-invasive hemoglobin level measurement was aimed with a combined DL model created by using nail images with age, height, weight, BMI, and gender information of the volunteers.


Eligibility criteria: Inclusion Criteria:

* Individuals need to be healthy.
* Individuals should not have any active hand or nail disease.
* Individuals should know their hemoglobin level.

Exclusion Criteria:

-In case of any condition that hides the natural nail color, such as henna, nail polish, protective or trauma-induced dents, bruises on the nails of individuals, it is removed from the study.

Primary outcomes:
measure: Bland-Altman analysis
timeFrame: 1 day
measure: Estimation accuracy analysis
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Karabük
country: Turkey
facility: Karabuk University
Study officials:
References:
Clinical trial NCT01660724: Ultrasound Guided Arterial Puncture
Official title: Ultrasound Guided Arterial Puncture: a Prospective, Blinded, Randomised Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arterial Puncture
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2012-08-09
Enrollment: 238
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The main purpose of the study is to evaluate whether the routine use of ultrasound guided arterial puncture can increase the proportion of patients who only needs one puncture attempt in order to successfully extract enough blood to make an arterial blood gas analysis, when ultrasound guided arterial puncture is compared to conventional arterial puncture technique.


Eligibility criteria: Inclusion Criteria:

* Patient admitted or treated in the acute emergency department
* Indication for a arterial blood gas analysis, according to the physician responsible for the patient's hospital stay / treatment

Exclusion Criteria:

* Patient age \< 16 years

Primary outcomes:
measure: The proportion of patients who only needs one puncture attempt in order to successfully extract enough blood to make an arterial blood gas analysis
timeFrame: up to 1 hour after arterial puncture
Secondary outcomes:
measure: Time used for arterial puncture
timeFrame: up to 1 hour after arterial puncture
measure: Patient corporation
timeFrame: up to 1 hour after arterial puncture
measure: Pain Scores on the Visual Analog Scale
timeFrame: Up to 1 hour after arterial puncture
measure: Number of attempts before successfully acquiring arterial puncture
timeFrame: up to 1 hour after arterial puncture
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Odense University Hospital
state: Fyn
Study officials:
affiliation: Odense Universityhospital
name: Christian B Laursen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Flumignan RL, Trevisani VF, Lopes RD, Baptista-Silva JC, Flumignan CD, Nakano LC. Ultrasound guidance for arterial (other than femoral) catheterisation in adults. Cochrane Database Syst Rev. 2021 Oct 12;10(10):CD013585. doi: 10.1002/14651858.CD013585.pub2.
Clinical trial NCT03709524: Orotracheal Intubation in Adult Patients: A Comparison of Standard Airtraq , Nasotracheal Airtraq Combined With a Stylet Inserted Endotracheal Tube and Standard Airtraq Combined Fiberoptic Intubation
Official title: A Comparison of Airtraq and Nasotracheal Airtraq for Orotracheal Intubation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Difficult Intubation
Lead sponsor: Kocaeli University
Sponsor class: OTHER
First posted: 2018-10-17
Enrollment: 119
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Adult patients requiring endotracheal intubation divided into three groups; standard Airtraq, Nasotracheal Airtraq + styletted endotracheal tube and Airtraq + fiberoptic combination groups.

Detailed description: We enroll lean adult patients requiring endotracheal intubation. Using a sealed envelope technique they divided into three groups; Standard Airtraq and Nasotracheal Airtraq + styletted endotracheal tube and Standard Airtraq + fiberoptic combination. Demographic characteristics and airway management variables such; age, gender, height, weight, ASA status, tooth morphology, tiro mental and sternomental distance were recorded. Insertion times, intubation times and total intubation times with these devices will be recorded. Hemodynamic parameters recorded such as; heart rate will be recorded baseline , after anesthesia, after insertion, just after and then every 2 minutes intervals after intubation. sore throat, hoarseness, dysphasia, bronchospasm were also recorded postoperatively.

Eligibility criteria: Inclusion Criteria:

* BMI\<30
* \> 18 AGE
* requiring endotracheal intubation
* ASA 1-2

Exclusion Criteria:

* BMI\> 30
* \< 18 AGE
* ASA III-IV
* upper respiratory infection past ten days
* pregnant

Primary outcomes:
measure: Intubation time
timeFrame: 6 months
Secondary outcomes:
measure: insertion time
timeFrame: 6 months
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Kocaeli University Medical Faculty
Study officials:
References:
Clinical trial NCT00170924: To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
Official title: A Multi-center, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diastolic Dysfunction
Hypertension
Keywords: Hypertension, High Blood Pressure, Diastolic Dysfunction,
Heart Disease
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-09-15
Enrollment: 317
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients who have had high blood pressure for a long time may have diastolic dysfunction. Diastolic Dysfunction is when your heart has difficulty filling and emptying, and relaxing adequately.

This study is to find out if Valsartan) will improve the ability of the heart to fill, empty, and relax appropriately when given alone or with other medicines to treat high blood pressure.


Eligibility criteria: Inclusion Criteria:

* Diagnosis/History of high blood pressure
* Male or Female age 45 years or older

Exclusion Criteria:

* History of stroke, transient ischemic attack or heart attack within the last 6 months
* A hospital admission for congestive heart failure within the last year
* Use of certain high blood pressure medications such as ACE inhibitors, Angiotensin Receptor Blockers or aldosterone antagonists or other agents that may work in the same pathway (RAAS) as valsartan within the past 3 months.

Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Change from baseline in diastolic heart function at 38 weeks, measured by echocardiogram
Secondary outcomes:
measure: Change from baseline in the wall thickness of left heart ventricle after 38 weeks
measure: Change from baseline in the size (mass) left heart ventricle after 38 weeks
measure: Change from baseline in heart function after 38 weeks
measure: Change from baseline in circulating marker of ventricular function after 38 weeks
measure: Change from baseline in circulating marker of inflammation
Other outcomes:
Locations:
city: East Hanover
country: United States
facility: Novartis Pharmaceuticals
state: New Jersey
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
citation: Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourciere Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP; Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23;369(9579):2079-87. doi: 10.1016/S0140-6736(07)60980-5.
Clinical trial NCT06730724: Thenar Muscle Ultrasound in CTS Evaluation
Official title: Is Ultrasound Measurement of Thenar Muscle Cross-Sectional Area Useful in the Evaluation of Carpal Tunnel Syndrome?: A Controlled Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Carpal Tunnel Syndrome
Lead sponsor: Beylikduzu State Hospital
Sponsor class: OTHER
First posted: 2024-12-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Carpal tunnel syndrome and healthy controls

Brief summary: This study will include 20 patients aged 18-75 years who have been diagnosed with carpal tunnel syndrome (CTS) based on electrophysiological examinations performed within the last three months, as well as 20 healthy volunteers without a CTS diagnosis. Sociodemographic data such as age, gender, height, weight, and BMI will be recorded. Pinch grip strength will be evaluated using a Jamar pinch meter, and hand grip strength will be assessed using a Jamar dynamometer. Ultrasound will be used to measure the cross-sectional area and thickness of the thenar muscles as well as the cross-sectional area of the median nerve. Additionally, previous electrophysiological examination results will be recorded for the CTS patients.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18-75 years.
* Diagnosed with carpal tunnel syndrome based on electrophysiological examination within the last 3 months.
* Healthy volunteers without a diagnosis of carpal tunnel syndrome.
* Volunteered to participate in the study.

Exclusion Criteria:

* Refusal to participate in the study.
* History of surgery due to carpal tunnel syndrome.
* Presence of neuromuscular diseases.
* Presence of advanced osteoarthritis.
* Presence of psychiatric disorders.
* Presence of cognitive impairments that may hinder study participation.

Primary outcomes:
measure: Thenar Muscle Cross-Sectional Area (Ultrasound)
timeFrame: 0 day
Secondary outcomes:
measure: Thenar Muscle Thickness (Ultrasound)
timeFrame: 0 day
measure: Median Nerve Cross-Sectional Area (Ultrasound)
timeFrame: 0 day
measure: Pinch Grip Strength
timeFrame: 0 day
measure: Hand Grip Strength
timeFrame: 0 day
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Beylikdüzü State Hospital
state: Beylikdüzü
Study officials:
affiliation: Beylikdüzü State Hospital
name: Büşra Şirin Ahısha
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03721224: Psychiatric Disorders in Children With Psychogenic Cough
Official title: Psychiatric Disorders and Clinical Features of Children With Psychogenic Cough
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psychogenic Cough
Keywords: psychiatry, children, habit cough
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2018-10-26
Enrollment: 94
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who were diagnosed as having psychogenic cough between 2015 and 2018 years. Age and gender matched control who don't have any chronical health problems.

Brief summary: The study aims to evaluate psychiatric disorders and clinical features of children with psychogenic cough. Psychiatric disorders are assessed via a semi-structured interview (Kiddie Schedule for Affective Disorders and Schizophrenia) and clinical features are investigated via sociodemographic form, which was developped by researchers. Investigator planned to compare psychiatric diagnoses, specifically anxiety and depression, with children referred to pediatric clinics.


Eligibility criteria: Inclusion Criteria:

* Having psychogenic cough for study group.
* Referred to pediatric clinics.

Exclusion Criteria:

* Chronical psychiatric disorder and pediatric disease history for control group.

Primary outcomes:
measure: Psychiatric disorders
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bezmialem Vakif University
state: Fatih
Study officials:
affiliation: Bezmialem University Department of Child and Adolescent Psychiatry
name: Abdurrahman Cahid Orengul
role: STUDY_DIRECTOR
References:
Clinical trial NCT00493324: Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
Official title: An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Plaque Psoriasis
Keywords: psoriasis
alefacept
polyvalent pneumococcal vaccine
Immunization
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2007-06-28
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

Detailed description: This is a 1 arm study designed to evaluate the immune response to pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

Eligibility criteria: Inclusion Criteria:

* Subject has chronic plaque psoriasis
* Subject has at least 5% body surface area affected with psoriasis

Exclusion Criteria:

* Skin disorder other than plaque psoriasis in affected area
* Previously immunized with any pneumococcal vaccine
* Subject has pustular or erythrodermic psoriasis
* Subject is immunocompromised
* Six or more herpes simplex virus outbreaks per year
* History or malignancy, chronic serious infection or hepatic disease

Primary outcomes:
measure: The number and percentage of subjects with at least a 2-fold increase in 2 or more of 5 pneumococcal antibody titers.
timeFrame: 12 weeks
Secondary outcomes:
measure: The number and percentage of subjects with an antibody response to pneumococcal antigens
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: San Diego
country: United States
state: California
city: New York
country: United States
state: New York
city: New York
country: United States
state: New York
city: Cleveland
country: United States
state: Ohio
city: St. John
country: Canada
state: Newfoundland and Labrador
city: Markham
country: Canada
state: Ontario
Study officials:
affiliation: Astellas Pharma US, Inc.
name: Use Central Contact
role: STUDY_DIRECTOR
References:
citation: Lynde C, Krell J, Korman N, Mathes B; Vaccine Study Investigators. Immune response to pneumococcal polysaccharide vaccine in adults with chronic plaque psoriasis treated with alefacept. J Am Acad Dermatol. 2011 Oct;65(4):799-806. doi: 10.1016/j.jaad.2010.04.040. Epub 2011 Mar 30.
Clinical trial NCT02158624: Ranibizumab Treatment for Age-Related Macular Degeneretion
Official title: The Correlation for Improvement of Visual Acuity and QOL After Ranibizmab Treatment for Age-Related Macular Degeneration Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Visual Disorder Due to Age-related Macula Degeneration
Lead sponsor: Kyushu University
Sponsor class: OTHER
Collaborators: name: University of Occupational and Environmental Health
name: Kurume University
name: Fukuoka University
name: Clinical Research Support Center Kyush
name: Novartis
First posted: 2014-06-09
Enrollment: 100
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To establish the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for AMD patients.


Eligibility criteria: Inclusion Criteria:

* Active primary or recurrent subfoveal choroidal neovascularization lesion due to AMD
* Subjects of either gender age 50 years or older
* Visual acuity better than 0.05 decimal( 20/400 Snellen)
* Signed informed consent form

Exclusion Criteria:

* Prior treatment for neovascular AMD in the study eye, for example, PDT or anti-VEGF therapy
* Patients whose lesion site evaluated by FA examination is more than 12DA in subject eye
* Patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye
* Patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye
* Patients with serious allergic history to such as fluorescein, indocyanine green, iodophors
* The pregnant or lactating woman

Primary outcomes:
measure: Baseline change of visual acuity and QOL after ranibizumab treatment
timeFrame: 3 months
Secondary outcomes:
measure: To evaluate the correlation between the changes of visual acuity and QOL measurement during one year follow-up observations
timeFrame: 1year
Other outcomes:
measure: Baseline change of central retinal thickness by OCT examination.
timeFrame: 3 months, 1 year
Locations:
city: Maidashi, Higashiku, Fukuoka-city
country: Japan
facility: Department of Ophthalmology, Kyushu University Hospital
state: Fukuoka
Study officials:
References: